Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (CRISIS INTERVENTION) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
2 findings from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes leaving the study early/ loss to compared with PLACEBO (very low certainty).
1 finding from 1 review
Clinical global response‐leaving the study early (short term) · patients with schizophrenia
DANCE THERAPY showed no clear difference in clinical global response‐leaving the study early (short term) compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Clinical global response‐leaving the study early (long term) · patients with schizophrenia
DANCE THERAPY showed no clear difference in clinical global response‐leaving the study early (long term) compared with STANDARD CARE (low certainty).
1 finding from 1 review
Adverse events Adverse events includes withdrawal and drop‐outs that could be clearly identified as due to an adverse event · patients with fibromyalgia
Acupuncture showed no clear difference in adverse events Adverse events includes withdrawal and drop‐outs that… compared with placebo or sham acupuncture (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis
1 finding from 1 review
Adverse effects: Leaving the study early · people with psychosis
1 finding from 1 review
Leaving the study early · patients with chronic mental illnesses
It is very uncertain whether life skills programme changes leaving the study early compared with standard care (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE/FGA (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Intervention not reported
Early neonatal death (0 to 6 days) · pregnant women giving birth
The intervention showed no clear difference in early neonatal death (0 to 6 days) (moderate certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to adverse effects (overall tolerability… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia
1 finding from 1 review